Subtopic Deep Dive

← Histone Deacetylase Inhibitors Research

Class-Specific Histone Deacetylase Inhibitors
Research Guide

What is Class-Specific Histone Deacetylase Inhibitors?

Class-specific histone deacetylase inhibitors are isoform-selective small molecules targeting individual HDAC classes (I-IV) to achieve precise epigenetic modulation with reduced off-target toxicity.

HDACs divide into four classes: class I (HDAC1-3,8), class IIa (HDAC4,5,7,9), class IIb (HDAC6,10), and class IV (HDAC11), each with distinct substrate preferences and cellular roles (de Ruijter et al., 2003; 3060 citations). Selectivity arises from structural differences in catalytic domains, enabling design of inhibitors like tubacin for HDAC6. Over 100 papers explore class-specific profiling since 2000.

Curated Papers

Key Challenges

Why It Matters

Class-specific HDAC inhibitors improve therapeutic indices by sparing non-oncogenic isoforms, reducing side effects seen in pan-HDACi like vorinostat (West and Johnstone, 2014). In cancer, HDAC6-selective inhibitors disrupt microtubule dynamics and aggresome function without broad gene derepression (Seto and Yoshida, 2014). Combination with chemotherapeutics enhances efficacy via synergistic pathway modulation (Bayat Mokhtari et al., 2017; 2374 citations). Clinical candidates like ricolinostat (HDAC6-specific) advanced to phase II trials for multiple myeloma.

Key Research Challenges

Achieving Isoform Selectivity

Designing inhibitors that discriminate between HDAC paralogs with >90% sequence identity in active sites remains difficult (Seto and Yoshida, 2014). Structure-activity relationship studies require high-resolution crystallography for class IIb pockets. Cross-reactivity with metalloproteases complicates profiling (West and Johnstone, 2014).

Profiling Selectivity Accurately

Standard fluorogenic assays overestimate selectivity due to substrate bias across classes (de Ruijter et al., 2003). Cellular thermal shift assays and CRISPR-validated models provide better readouts but scale poorly. Off-target effects on non-histone substrates evade detection (Li and Seto, 2016).

Optimizing Pharmacokinetics

Class II inhibitors often suffer poor bioavailability from polar zinc-binding groups (Arrowsmith et al., 2012). Brain penetration for class IV HDAC11 remains elusive despite neurodegeneration links. Resistance via HDAC upregulation demands combination strategies (Eckschlager et al., 2017).

Essential Papers

Histone deacetylases (HDACs): characterization of the classical HDAC family

Annemieke J.M. de Ruijter, Albert H. Gennip, Huib N. Caron et al. · 2003 · Biochemical Journal · 3.1K citations

Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as ...

Combination therapy in combating cancer

Reza Bayat Mokhtari, Tina S. Homayouni, Narges Baluch et al. · 2017 · Oncotarget · 2.4K citations

Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy. The amalgamation of anti-cancer drugs enhances efficacy compared to the m...

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Saverio Minucci, Pier Giuseppe Pelicci · 2006 · Nature reviews. Cancer · 2.2K citations

Erasers of Histone Acetylation: The Histone Deacetylase Enzymes

Ed Seto, Minoru Yoshida · 2014 · Cold Spring Harbor Perspectives in Biology · 1.9K citations

Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl functional groups from the lysine residues of both histone and nonhistone proteins. In humans, there are 18 HDAC enzymes...

New and emerging HDAC inhibitors for cancer treatment

Alison C. West, Ricky W. Johnstone · 2014 · Journal of Clinical Investigation · 1.3K citations

Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner p...

Epigenetic protein families: a new frontier for drug discovery

C.H. Arrowsmith, C. Bountra, Paul V. Fish et al. · 2012 · Nature Reviews Drug Discovery · 1.3K citations

HDACs and HDAC Inhibitors in Cancer Development and Therapy

Yixuan Li, Edward Seto · 2016 · Cold Spring Harbor Perspectives in Medicine · 1.2K citations

Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Post-translational modifications of histones, for example, may play a crucial...

Reading Guide

Foundational Papers

Start with de Ruijter et al. (2003; 3060 citations) for HDAC family classification, then Seto and Yoshida (2014; 1905 citations) for enzyme mechanisms, followed by West and Johnstone (2014; 1339 citations) for selective inhibitor examples.

Recent Advances

Li and Seto (2016; 1225 citations) covers therapy applications; Eckschlager et al. (2017; 1143 citations) details anticancer mechanisms; Bayat Mokhtari et al. (2017; 2374 citations) on combinations.

Core Methods

Fluor-de-Lys assays for IC50; X-ray crystallography for zinc-binding motifs; CRISPR knockout for validation; cellular thermal shift assay (CETSA) for selectivity.

How PapersFlow Helps You Research Class-Specific Histone Deacetylase Inhibitors

Discover & Search

Research Agent uses searchPapers('class-specific HDAC inhibitors HDAC6 selectivity') to retrieve West and Johnstone (2014), then citationGraph to map 500+ citing works on isoform profiling, and findSimilarPapers to uncover HDAC11-selective leads from exaSearch semantic queries.

Analyze & Verify

Analysis Agent applies readPaperContent on Seto and Yoshida (2014) to extract class-specific mechanisms, verifyResponse with CoVe against de Ruijter et al. (2003) for classification accuracy, and runPythonAnalysis to plot IC50 selectivity ratios from supplemental tables using pandas, graded by GRADE for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in HDAC4/5 class IIa inhibitors via contradiction flagging across Minucci and Pelicci (2006) reviews, while Writing Agent uses latexEditText for structure-activity tables, latexSyncCitations for 50-paper bibliographies, and latexCompile to generate submission-ready manuscripts with exportMermaid for inhibitor SAR diagrams.

Use Cases

"Analyze IC50 data from 5 HDAC6 inhibitor papers and plot selectivity vs HDAC1."

Research Agent → searchPapers → Analysis Agent → readPaperContent (West 2014) → runPythonAnalysis (pandas IC50 curve fitting, matplotlib log-scale plot) → researcher gets publication-quality selectivity graph with statistical p-values.

"Draft LaTeX review on class IIb HDAC inhibitors with citations."

Synthesis Agent → gap detection → Writing Agent → latexEditText (structure outline) → latexSyncCitations (Seto 2014, de Ruijter 2003) → latexCompile → researcher gets PDF with auto-formatted equations and 20 synced references.

"Find GitHub repos with HDAC inhibitor docking code from recent papers."

Research Agent → citationGraph (Arrowsmith 2012) → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → researcher gets verified AutoDock scripts for class-specific binding models with install instructions.

Automated Workflows

Deep Research workflow scans 50+ papers on class-specific inhibitors via searchPapers → citationGraph → structured report with GRADE-scored efficacy data. DeepScan's 7-step chain verifies selectivity claims (readPaperContent → CoVe → runPythonAnalysis on dose-response curves). Theorizer generates hypotheses on HDAC11 druggability from Arrowsmith et al. (2012) abstracts.

Try Doxa for Class-Specific Histone Deacetylase Inhibitors Research

Frequently Asked Questions

What defines HDAC classes for inhibitor design?

Class I (HDAC1-3,8) are nuclear zinc-enzymes; class IIa (4,5,7,9) shuttle nucleus-cytoplasm; class IIb (6,10) are cytoplasmic; class IV (11) shares class I homology (de Ruijter et al., 2003).

What methods develop class-specific inhibitors?

Structure-based design uses HDAC6-tubacin templates; fragment screening targets class IIa shuttling domains; cellular assays measure substrate-specific deacetylation (West and Johnstone, 2014).

Which papers define the field?

de Ruijter et al. (2003; 3060 citations) classifies classical HDACs; Seto and Yoshida (2014; 1905 citations) details 18 isoforms; West and Johnstone (2014; 1339 citations) reviews selective candidates.

What open problems exist?

HDAC11-selective inhibitors lack due to unique cap domain; pan-class II resistance mechanisms undefined; non-histone substrate profiling incomplete (Li and Seto, 2016).